resistance of the causative organism are the result of human actions. 1 They are man-made for three reasons: (i) conditions that promote the dissemination and development of active disease are the result of socio-economic problems, such as homelessness, poverty, over-crowded living accommodation and the poor or undeveloped delivery of medical care. 2 (ii) The development of drug resistance is the result of selection of resistant strains by sub-optimal treatment regimens or poor patient compliance. 3, 4 (iii) In countries that are economically disadvantaged and where rapid laboratory procedures required for the delivery of antibiotic susceptibility data are not available, the management of the infection takes place blindly. 5 Unless all of these conditions are corrected, the dissemination of this problematic infection will increase. 1 It is beyond scientists and physicians alone to bring about improvement of economic conditions so as to provide rapid antibiotic susceptibility tests, or to support the provision of four or five costly antibiotics to patients with infections predictably responsive to these agents, or still more expensive antibiotics when first-line agents are predicted to be ineffective. Nevertheless, there is an alternative that has the potential to treat patients effectively regardless of the antibiotic susceptibility profile of the causative organism at a cost that is affordable by the most economically deprived country. This same alternative also has potential as an adjunct to conventional therapy during the lengthy period before antibiotic susceptibility data are available. It has the potential to serve as an adjunct that may reduce morbidity associated with the use of rifampicin and streptomycin by allowing their use in lower dosages. It is therefore our intent in this review to provide cogent and comprehensive evidence supporting the contention that phenothiazines, and specifically thioridazine, may eventually facilitate the successful and safe management of many infections caused by M. tuberculosis, regardless of susceptibility profile.
The potential solution
The phenothiazine group are tricyclic compounds ( Figure) . Methylene blue, the first phenothiazine, is an aniline dye. The biological properties of this aniline dye were studied by Ehrlich, 6, 7 who demonstrated that it had activity against Plasmodium falciparum, and when administered to patients would cause them to become lethargic. 8 The narcotizing properties of methylene blue and subsequent phenothiazines were of greater interest to the biomedical community than its antimicrobial ones, eventually resulting in the development of the first neuroleptic compound, chlorpromazine, in the early 1950s. 5, 9, 10 The wide acceptance and use of chlorpromazine in the ensuing years for the management of severe neuroses and psychoses yielded a few anecdotal reports suggesting that this agent had anti-tuberculosis properties. [11] [12] [13] [14] Although these findings were preceded by studies that showed that this compound, as well as promethazine, had in vitro activity against M. tuberculosis, [15] [16] [17] interest in the development of these compounds as antimycobacterial agents did not materialize because of the by then well-known severe side effects produced by the chronic administration of chlorpromazine. Furthermore, the introduction of isoniazid in the 1950s for the management of infections by M. tuberculosis, later followed by other effective compounds (streptomycin and rifampicin), lessened any further interest in the use of chlorpromazine as an anti-tuberculosis drug.
18 Nevertheless, during the next few decades a number of studies indicated that chlorpromazine and its derivatives had in vitro activity against M. tuberculosis and that the anti-histaminic phenothiazine methdilazine was similarly effective. [19] [20] [21] [22] However, the lowest concentration required for significant in vitro inhibition of growth greatly exceeded that achievable in patients (i.e. about 0.5 mg/L) receiving a minimum dose of 600 mg/day. Nevertheless, concomitant studies also showed that M. tuberculosis phagocytosed within macrophages was susceptible to concentrations of chlorpromazine 10 times lower in the culture medium than those needed for a similar inhibition of unphagocytosed bacteria.
18 These concentrations were within the range anticipated in patients treated with this phenothiazine. 9 These results suggested that macrophages had the ability to concentrate the phenothiazine, an interpretation consistent with those studies showing that chlorpromazine was found in pulmonary tissue in concentrations in excess of 100 times those in plasma. 23 The ability of phenothiazines and their derivatives to inhibit the growth in vitro and in vivo of M. tuberculosis is not by itself of any major significance in light of the number of available antibiotics that have been successfully employed in the past for the management of tuberculosis. However, the worldwide resurgence of tuberculosis and the escalating frequency of resistant strains, as discussed in the Introduction, predicate an urgent need for more drugs. Ideally, these should be effective against all strains of M. tuberculosis regardless of antibiotic susceptibility, 3, 4 sufficiently inexpensive that their availability to the poorest patient is assured, of good tolerability and active against a multiplicity of targets so as to lessen the probability of selecting resistant mutants. If these parameters can be potentially satisfied by one single drug, then that possibility is worthy of consideration now.
Thioridazine: the phenothiazine that has the potential to satisfy all current needs for the management of antibiotic-resistant pulmonary tuberculosis Chlorpromazine, the first commercially produced phenothiazine for the management of psychosis, was also one of the first of the phenothiazine series shown to have antituberculosis properties in vitro and in vivo. 14, 16 Since that first in vitro demonstration, chlorpromazine and other phenothiazines have been shown to inhibit the growth in vitro of M. tuberculosis. 5, [18] [19] [20] [21] [22] [24] [25] [26] [27] [28] [29] [30] [31] [32] The MICs of a number of phenothiazines for M. tuberculosis are given in Table I , as well as the system employed for the determination of antitubercular activity. The identification of the system employed is important inasmuch as assays differ with respect to the criteria employed for defining inhibition. The MICs of chlorpromazine, the phenothiazine that has received the most attention, range from 0.9 mg/L to as high as 32 mg/L. The lowest effective in vitro concentration against M. tuberculosis is seen after the organism has been phagocytosed by human macrophages. 18 In the absence of macrophages the MIC is almost 10-fold higher, which is a consequence of the ability of macrophages to concentrate chlorpromazine many times over that in the medium.
18-24,33 It should be noted that chlorpromazine at concentrations comparable to in vitro MICs in the absence of macrophages inhibits the transport of calcium by binding to the calcium-binding protein calmodulin. [34] [35] [36] This inhibition affects the integrity of the phagocytic process and is thus the basis for the in vitro exposure of the macrophage to the drug after the completion of the phagocytic process. 37, 38 The in vitro activity of chlorpromazine against clinical isolates of M. tuberculosis in the absence of macrophages is similar regardless of the testing system employed (Table I) . Moreover, all strains of M. tuberculosis tested so far, regardless of whether they are susceptible to all agents, or are multi-or polydrug resistant, or even resistant to all five primary antibiotics, are equally affected by chlorpromazine (Table II) . 5, 21, 31 Of significance is the observation that the activity of thioridazine, a very mild phenothiazine neuroleptic, against these strains is identical to that of chlorpromazine (Table II) .
The extensive use of chlorpromazine for the management of psychosis during the past 40 years provided abundent evidence for this compound producing severe side effects when administered over long periods. The more serious side effects are liver injury (acute and chronic), 39 cholestatic disease and agranulocytosis. 40, 41 Chronic use of thioridazine can result in transient mild retinopathy. 42 Although chronic use of thioridazine in experimental animals produces mild to severe cardiotoxicity, 43 with the exception of overdoses (suicide attempts) and co-administration with potentially cardiotoxic drugs, 44-46 chronic use of thioridazine alone has not been observed to produce similar effects. The published side effects noted with the chronic administration of either chlorpromazine or thioridazine are given in Table III . The severe side effects associated with chlorpromazine are totally absent with thioridazine. Indeed, drowsiness is the most common side effect noted.
As stated above, interest in the development of chlorpromazine for treating tuberculosis was previously minimal because management of this infection with conventional antibiotics was effective. The emergence of increasingly antibiotic-resistant strains in many parts of the world, including the main urban centres of Western Europe, is now causing great concern. 1 In the United States, the These guidelines were successful in that infection rates in 1999 were below those of the 1950s. Although this approach will undoubtedly succeed in many parts of the world, there is reason to believe that it will fail in certain parts of Western and Eastern Europe, Africa, Asia and South America, because large numbers of infections are resistant to four or more conventional antibiotics. 48 The upward spiral of infection is therefore anticipated to continue. 49 For these reasons, interest in phenothiazines as potential treatment of tuberculosis is increasing, as evidenced by the number of published studies in recent years showing that these compounds have potential value. 5, 18, 21, 24 Nevertheless, resistance to their use continues as a consequence of the well-known side effects associated with the chronic use of chlorpromazine, as well as the knowledge that the in vitro concentrations of phenothiazines required for inhibiting the growth of M. tuberculosis are beyond those that are clinically achievable. 24 These two objections are now obviated by observations that clearly show that the very mild phenothiazine thioridazine is as active as chlorpromazine and that in all probability the effective concentrations noted in vitro are reproduced within the macrophage that has phagocytosed the organism.
The use of thioridazine as the phenothiazine of choice for the management of freshly diagnosed pulmonary tuberculosis is further reinforced by the observations that this compound enhances the in vitro activity of rifampicin and streptomycin against polydrug-resistant strains of M. tuberculosis. 32 Chlorpromazine also enhances the in vitro and in vivo activity of these antibiotics against antibiotic susceptible and polydrug-resistant strains of M. tuberculosis.
18,31
These observations suggest that the use of thioridazine may allow a reduction in the dosages of these antibiotics and the morbidity associated with these antibiotics may therefore be reduced.
18,32
The use of thioridazine for the management of tuberculosis affords another potential advantage, namely that mutations resulting in resistance to the drug are not anticipated since calmodulin, the calcium transport protein of eukaryotic cells and to which the phenothiazine binds and renders inactive, is also a vital constituent of the cell wall envelope of mycobacteria.
25,26,50,51 Deletions of this gene or mutations that affect the binding of calcium would most probably be lethal. In addition, the phenothiazine affects a large number of targets that are required for the survival of the organism, 27,51 and thus, even if mutations were to take place, the probability that all of these mutations would occur in one single cell, is very remote. 
Conclusions
The review provides fairly strong evidence that the phenothiazine thioridazine may, in certain patients, prove useful for the management of tuberculosis infections. In the case of full-blown cavitary disease, where the organism is primarily extracellular, little or no activity is anticipated since the concentrations required are in excess of those clinically achievable. Nevertheless, for moderate cavitary disease, and in patients probably infected with multidrugresistant strains, the use of thioridazine while awaiting antibiotic susceptibility results may provide effective treatment as well as contributing to a reduction in the dissemination of infection. However, this possibility presently remains conjectural since there is much that is still unknown. The questions of whether thioridazine is concentrated by macrophages that have phagocytosed M. tuberculosis and whether it is active in situ remain to be answered. Furthermore, even if they were to be answered affirmatively, the question of whether this compound will be similarly effective in patients must be resolved. To this extent we must await the results of further in vitro and in vivo (macrophage and animal) studies before thioridazine may start to find its place in the armamentarium of antituberculosis drugs. 
